Abstract：
Cancer stands as a prominent global cause of mortality, necessitating early detection to augment survival rates and alleviate economic burdens on healthcare systems. In particular, prostate cancer (PCa), impacting 1.41 million men globally in 2020, accentuates the demand for sensitive and cost-effective detection methods beyond traditional prostate-specific antigen (PSA) testing. While clinical techniques exhibit limitations, biosensors emerge as compact, user-friendly alternatives to traditional laboratory approaches. However, existing biosensors predominantly concentrate on PSA detection, prompting the necessity for advancing toward multiplex sensing platforms. This study introduces a compact opto-microfluidic sensor featuring a substrate of gold nanospikes, fabricated via electrodeposition, for enhanced sensitivity. Embedded within a microfluidic chip, this nanomaterial enables the precise and concurrent measurement of PSA, alongside two complementary PCa biomarkers, matrix metalloproteinase-2 (MMP-2) and anti-α-methylacyl-CoA racemase (anti-AMACR) in diluted human plasma, offering a comprehensive approach to PSA analysis. Taking advantage of the localized surface plasmon resonance principle, this biosensor offers robustness and sensitivity in real sample analysis without the need for labeling agents. With the limit of detection at 0.22, 0.37, and 0.18 ng/mL for PSA, MMP-2, and anti-AMACR, respectively, this biosensing platform holds promise for point-of-care analysis, underscoring its potential impact on medical diagnostics.
摘要：
癌症是全球主要的死亡原因，需要早期检测以提高生存率并减轻医疗系统的经济负担。特别是,前列腺癌（PCa），在2020年影响全球141万男性，突出了对传统前列腺特异性抗原（PSA）检测之外的敏感和具有成本效益的检测方法的需求。虽然临床技术表现出局限性，生物传感器变得紧凑，用户友好的替代传统的实验室方法。然而,现有的生物传感器主要集中在PSA检测上，促使人们有必要向多路传感平台迈进。这项研究介绍了一种紧凑的光-微流体传感器，其特征是金纳米尖峰的基底，通过电沉积制造，增强灵敏度。嵌入微流控芯片中，这种纳米材料能够精确和同时测量PSA，除了两个互补的PCa生物标志物，稀释的人血浆中的基质金属蛋白酶-2（MMP-2）和抗-α-甲基酰基辅酶A消旋酶（抗-AMACR），提供全面的PSA分析方法。利用局域化表面等离子体共振原理,这种生物传感器在实际样品分析中提供了鲁棒性和灵敏度，而不需要标记试剂。PSA的检测限为0.22、0.37和0.18ng/mL，MMP-2和抗AMACR，分别,这个生物传感平台有望进行即时分析，强调其对医疗诊断的潜在影响。
